Orexin (OX) levels are elevated in the cerebrospinal fluid of patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD).
Objective
To investigate the efficacy of dual OX receptor antagonists (suvorexant and lemborexant) in an early-stage AD mouse model (App-KI).
Methods
OX receptor gene expression was measured. Additionally, drug distribution and effects on motor activity following single oral administration of suvorexant and lemborexant were assessed. Furthermore, cognitive function, amyloid-β (Aβ) levels and uptake by microglia in the hippocampal CA1 region were evaluated following daily administration of suvorexant and lemborexant for 60 days.
Results
OXR gene expression was highest in the lateral hypothalamus of wild-type mice and was also observed in other brain regions. OX1R gene expression was significantly increased in these brain regions in App-KI mice. In wild-type mice, brain concentrations of suvorexant peaked 20 to 40 min after administration, and those of lemborexant peaked 15 min after administration. Concentrations subsequently declined but remained detectable 24 h after administration. Additionally, motor activity decreased following the administration of either suvorexant or lemborexant; however, no difference in motor activity was observed compared to the control group 24 h later. Notably, the Y-maze test revealed that suvorexant and lemborexant mitigated cognitive impairment in App-KI mice. Furthermore, both drugs suppressed the accumulation of Aβ in the CA1 region of the hippocampus in App-KI mice. This was associated with increased Aβ uptake by activated microglia.
Conclusions
The results suggest that suvorexant and lemborexant effectively suppresses the early stages of AD.
PetersenRCLopezOArmstrongMJ, et al.Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology2018; 90: 126–135.
2.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 270–279.
3.
DuboisBFeldmanHHJacovaC, et al.Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol2014; 13: 614–629.
4.
WattmoCLondosEMinthonL. Longitudinal associations between survival in Alzheimer's disease and cholinesterase inhibitor use, progression, and community-based services. Dement Geriatr Cogn Disord2015; 40: 297–310.
5.
SolopovaERomero-FernandezWHarmsenH, et al.Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease. Nat Commun2023; 14: 8220.
6.
SwansonCJZhangYDhaddaS, et al.A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther2021; 13: 80.
7.
SwansonCJZhangYDhaddaS, et al.Correction to: a randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther2022; 14: 70.
8.
ZimmerJAArdayfioPWangH, et al.Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol2025; 82: 461–469.
9.
GabelleAJaussentIHirtzC, et al.Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. Neurobiol Aging2017; 53: 59–66.
10.
LiguoriCChiaravallotiANuccetelliM, et al.Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease. J Neurol2017; 264: 2215–2223.
11.
SakuraiTAmemiyaAIshiiM, et al.Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell1998; 92: 573–585.
12.
ZhangSWangPJiB, et al.Signal transduction, dimerization, and therapeutic targeting of Orexin and receptor systems. Front Pharmacol2025; 16: 1697406.
13.
de LeceaLKilduffTSPeyronC, et al.The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A1998; 95: 322–327.
14.
PeyronCTigheDKvan den PolAN, et al.Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci1998; 18: 9996–10015.
15.
SakuraiT. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci2007; 8: 171–181.
16.
AllardJSTizabiYShafferyJP, et al.Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides2004; 38: 311–315.
17.
FronczekRvan GeestSFrölichM, et al.Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol Aging2012; 33: 1642–1650.
18.
IliffJJWangMLiaoY, et al.A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med2012; 4: 147ra111.
19.
KitamuraEHamadaJKanazawaN, et al.The effect of orexin-A on the pathological mechanism in the rat focal cerebral ischemia. Neurosci Res2010; 68: 154–157.
20.
LiguoriCNuccetelliMIzziF, et al.Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease. Neurobiol Aging2016; 40: 120–126.
21.
NishinoSKanbayashiT. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev2005; 9: 269–310.
22.
NishinoSRipleyBOvereemS, et al.Hypocretin (orexin) deficiency in human narcolepsy. Lancet2000; 355: 39–40.
23.
NishinoSRipleyBOvereemS, et al.Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol2001; 50: 381–388.
24.
SalomonRMRipleyBKennedyJS, et al.Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol Psychiatry2003; 54: 96–104.
25.
SharkeyRJCorteseFGoodyearBG, et al.Longitudinal analysis of glymphatic function in amyotrophic lateral sclerosis and primary lateral sclerosis. Brain2024; 147: 4026–4032.
26.
ThannickalTCMooreRYNienhuisR, et al.Reduced number of hypocretin neurons in human narcolepsy. Neuron2000; 27: 469–474.
27.
XieLKangHXuQ, et al.Sleep drives metabolite clearance from the adult brain. Science2013; 342: 373–377.
28.
LiuZWangFTangM, et al.Amyloid β and tau are involved in sleep disorder in Alzheimer's disease by orexin A and adenosine A(1) receptor. Int J Mol Med2019; 43: 435–442.
29.
GaoFLiuTTuoM, et al.The role of orexin in Alzheimer disease: from sleep-wake disturbance to therapeutic target. Neurosci Lett2021; 765: 136247.
30.
BeuckmannCTSuzukiMUenoT, et al.In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist. J Pharmacol Exp Ther2017; 362: 287–295.
31.
WinrowCJGotterALCoxCD, et al.Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet2011; 25: 52–61.
32.
KangJELimMMBatemanRJ, et al.Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science2009; 326: 1005–1007.
33.
LuceyBPLiuHToedebuschCD, et al.Suvorexant acutely decreases tau phosphorylation and Aβ in the human CNS. Ann Neurol2023; 94: 27–40.
34.
ZhouFYanXDWangC, et al.Suvorexant ameliorates cognitive impairments and pathology in APP/PS1 transgenic mice. Neurobiol Aging2020; 91: 66–75.
35.
ZhouMLiY. Effect of different doses of almorexant on learning and memory in 8-month-old APP/PS1 (AD) mice. Peptides2023; 167: 171044.
36.
DurairajaASteineckeCSFendtM. Intracerebroventricular infusion of the selective orexin 1 receptor antagonist SB-334867 impairs cognitive flexibility in a sex-dependent manner. Behav Brain Res2022; 424: 113791.
37.
GaoWRHuXHYuKY, et al.Selective orexin 1 receptor antagonist SB-334867 aggravated cognitive dysfunction in 3xTg-AD mice. Behav Brain Res2023; 438: 114171.
38.
HuXHYuKYLiXX, et al.Selective orexin 2 receptor blockade alleviates cognitive impairments and the pathological progression of Alzheimer's disease in 3xTg-AD mice. J Gerontol A Biol Sci Med Sci2024; 79: glae115.
39.
SaitoTMatsubaYMihiraN, et al.Single app knock-in mouse models of Alzheimer's disease. Nat Neurosci2014; 17: 661–663.
40.
SasaguriHNilssonPHashimotoS, et al.APP Mouse models for Alzheimer's disease preclinical studies. EMBO J2017; 36: 2473–2487.
41.
HadaKWulaerBNagaiT, et al.Mice carrying a schizophrenia-associated mutation of the Arhgap10 gene are vulnerable to the effects of methamphetamine treatment on cognitive function: association with morphological abnormalities in striatal neurons. Mol Brain2021; 14: 21.
42.
VentzkeKOsterHJöhrenO. Diurnal regulation of the orexin/hypocretin system in mice. Neuroscience2019; 421: 59–68.
43.
FranklinKPaxinosG. The Mouse brain in stereotaxic coordinates. San Diego, CA: Academic Press, 1997.
44.
ManoYUenoTHottaK. Establishment of a simultaneous assay for lemborexant, a novel dual orexin receptor antagonist, and its three metabolites, and its application to a clinical protein binding study. J Pharm Biomed Anal2020; 187: 113359.
45.
SkillmanBKS. Identification of suvorexant in blood using LC-MS-MS: important considerations for matrix effects and quantitative interferences in targeted assays. J Anal Toxicol2020; 44: 245–255.
46.
SkillmanBKerriganS. Drug-mediated ion suppression and mitigation of interferences using liquid chromatography-quadrupole/time of flight mass spectrometry (LC-Q/TOF-MS) and liquid chromatography tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci2020; 1152: 122265.
47.
SkillmanBKerriganS. CYP450-Mediated Metabolism of suvorexant and investigation of metabolites in forensic case specimens. Forensic Sci Int2020; 312: 110307.
48.
TakaseSLiaoJLiuY, et al.Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia. Eur J Pharmacol2022; 931: 175207.
49.
SawahataMAsanoHNagaiT, et al.Microinjection of Reelin into the mPFC prevents MK-801-induced recognition memory impairment in mice. Pharmacol Res2021; 173: 105832.
50.
YamadaKHiramatsuMNodaY, et al.Role of nitric oxide and cyclic GMP in the dizocilpine-induced impairment of spontaneous alternation behavior in mice. Neuroscience1996; 74: 365–374.
51.
YamadaKNodaYHasegawaT, et al.The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J Pharmacol Exp Ther1996; 276: 460–466.
52.
WulaerBNagaiTSobueA, et al.Repetitive and compulsive-like behaviors lead to cognitive dysfunction in Disc1(Delta2-3/Delta2-3) mice. Genes Brain Behav2018; 17: e12478.
53.
SaifullahMABKomineODongY, et al.Touchscreen-based location discrimination and paired associate learning tasks detect cognitive impairment at an early stage in an App knock-in mouse model of Alzheimer's disease. Mol Brain2020; 13: 147.
54.
SobueAKomineOEndoF, et al.Microglial cannabinoid receptor type II stimulation improves cognitive impairment and neuroinflammation in Alzheimer's disease mice by controlling astrocyte activation. Cell Death Dis2024; 15: 858.
55.
MarcusJNAschkenasiCJLeeCE, et al.Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol2001; 435: 6–25.
56.
TrivediPYuHMacNeilDJ, et al.Distribution of orexin receptor mRNA in the rat brain. FEBS Lett1998; 438: 71–75.
57.
MoriguchiSInagakiRSaitoT, et al.Propolis promotes memantine-dependent rescue of cognitive deficits in APP-KI mice. Mol Neurobiol2022; 59: 4630–4646.
58.
LoryanIHammarlund-UdenaesMSyvänenS. Brain distribution of drugs: pharmacokinetic considerations. Handb Exp Pharmacol2022; 273: 121–150.
59.
BeuckmannCTSuzukiHMusiekES, et al.Evaluation of SAMP8 mice as a model for sleep-wake and rhythm disturbances associated with Alzheimer's disease: impact of treatment with the dual orexin (hypocretin) receptor antagonist lemborexant. J Alzheimers Dis2021; 81: 1151–1167.
60.
BeuckmannCTUenoTNakagawaM, et al.Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep2019; 42: zsz076.
61.
BreidingerSASimpsonRCManginE, et al.Determination of suvorexant in human plasma using 96-well liquid-liquid extraction and HPLC with tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci2015; 1002: 254–259.
62.
KeenanRJDaykinHMethaJ, et al.Orexin 2 receptor antagonism sex-dependently improves sleep/wakefulness and cognitive performance in tau transgenic mice. Br J Pharmacol2024; 181: 87–106.
63.
SunHKennedyWPWilbrahamD, et al.Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep2013; 36: 259–267.
64.
PalmqvistSSchöllMStrandbergO, et al.Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun2017; 8: 1214.
65.
MorminoECKluthJTMadisonCM, et al.Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain2009; 132: 1310–1323.
66.
ZhengHZhouQDuY, et al.The hypothalamus as the primary brain region of metabolic abnormalities in APP/PS1 transgenic mouse model of Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis2018; 1864: 263–273.
67.
ChételatGArbizuJBarthelH, et al.Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurol2020; 19: 951–962.
68.
YeQGastGSuX, et al.Hippocampal neural circuit connectivity alterations in an Alzheimer's disease mouse model revealed by monosynaptic rabies virus tracing. Neurobiol Dis2022; 172: 105820.
69.
LeeCYLandrethGE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna)2010; 117: 949–960.
70.
FuHLiuBFrostJL, et al.Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia. Glia2012; 60: 993–1003.
71.
FujitaYMaedaTSatoC, et al.Engulfment of toxic amyloid β-protein in neurons and astrocytes mediated by MEGF10. Neuroscience2020; 443: 1–7.
72.
TsuneokaYFunatoH. Whole brain mapping of orexin receptor mRNA expression visualized by branched in situ hybridization chain reaction. eNeuro2024; 11: ENEURO.0474–23.2024.
73.
NambuTSakuraiTMizukamiK, et al.Distribution of orexin neurons in the adult rat brain. Brain Res1999; 827: 243–260.
74.
HarrisGCWimmerMAston-JonesG. A role for lateral hypothalamic orexin neurons in reward seeking. Nature2005; 437: 556–559.
75.
KarimiSHamidiGFatahiZ, et al.Orexin 1 receptors in the anterior cingulate and orbitofrontal cortex regulate cost and benefit decision-making. Prog Neuropsychopharmacol Biol Psychiatry2019; 89: 227–235.
76.
KotzCMTeskeJALevineJA, et al.Feeding and activity induced by orexin A in the lateral hypothalamus in rats. Regul Pept2002; 104: 27–32.
77.
MaZJiangWZhangEE. Orexin signaling regulates both the hippocampal clock and the circadian oscillation of Alzheimer's disease-risk genes. Sci Rep2016; 6: 36035.
78.
MavanjiVButterickTADuffyCM, et al.Orexin/hypocretin treatment restores hippocampal-dependent memory in orexin-deficient mice. Neurobiol Learn Mem2017; 146: 21–30.
79.
ThorpeAJKotzCM. Orexin A in the nucleus accumbens stimulates feeding and locomotor activity. Brain Res2005; 1050: 156–162.
80.
YangLZouBXiongX, et al.Hypocretin/orexin neurons contribute to hippocampus-dependent social memory and synaptic plasticity in mice. J Neurosci2013; 33: 5275–5284.
81.
BurtJAlbertoCOParsonsMP, et al.Local network regulation of orexin neurons in the lateral hypothalamus. Am J Physiol Regul Integr Comp Physiol2011; 301: R572–R580.
82.
LandryIAluriJHallN, et al.Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexant. Pharmacol Res Perspect2020; 8: e00678.
83.
YueJLChangXWZhengJW, et al.Efficacy and tolerability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis. Sleep Med Rev2023; 68: 101746.
84.
MahoneyCEMochizukiTScammellTE. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. Sleep2020; 43: zsz302.
85.
TsunekiHKonKItoH, et al.Timed inhibition of orexin system by suvorexant improved sleep and glucose metabolism in type 2 diabetic db/db mice. Endocrinology2016; 157: 4146–4157.
86.
SakakibaraYSekiyaMSaitoT, et al.Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer's disease. BMC Neurosci2019; 20: 13.
87.
GattazWFMarasACairnsNJ, et al.Decreased phospholipase A2 activity in Alzheimer brains. Biol Psychiatry1995; 37: 13–17.
88.
KrishnanBKayedRTaglialatelaG. Elevated phospholipase D isoform 1 in Alzheimer's disease patients’ hippocampus: relevance to synaptic dysfunction and memory deficits. Alzheimers Dement (N Y)2018; 4: 89–102.
89.
RossBMMoszczynskaAErlichJ, et al.Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J Neurochem1998; 70: 786–793.
90.
AnHChoMHKimDH, et al.Orexin impairs the phagocytosis and degradation of amyloid-β fibrils by microglial cells. J Alzheimers Dis2017; 58: 253–261.
91.
IshidaKYamadaKNishiyamaR, et al.Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration. J Exp Med2022; 219: e20211275.
92.
Domínguez-PrietoMVelascoATaberneroA, et al.Endocytosis and transcytosis of amyloid-β peptides by astrocytes: a possible mechanism for amyloid-β clearance in Alzheimer's disease. J Alzheimers Dis2018; 65: 1109–1124.
93.
NieoullonA. Dopamine and the regulation of cognition and attention. Prog Neurobiol2002; 67: 53–83.
94.
Švob ŠtracDPivacNMück-ŠelerD. The serotonergic system and cognitive function. Transl Neurosci2016; 7: 35–49.
95.
VolkLChiuSLSharmaK, et al.Glutamate synapses in human cognitive disorders. Annu Rev Neurosci2015; 38: 127–149.
96.
LiYSunHChenZ, et al.Implications of GABAergic neurotransmission in Alzheimer's disease. Front Aging Neurosci2016; 8: 31.
97.
PepeuGGiovanniniMG. Changes in acetylcholine extracellular levels during cognitive processes. Learn Mem2004; 11: 21–27.
98.
AracriPBanfiDPasiniME, et al.Hypocretin (orexin) regulates glutamate input to fast-spiking interneurons in layer V of the Fr2 region of the murine prefrontal cortex. Cereb Cortex2015; 25: 1330–1347.
99.
LiuRJvan den PolANAghajanianGK. Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci2002; 22: 9453–9464.
100.
NakamuraTUramuraKNambuT, et al.Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res2000; 873: 181–187.
101.
Calvo-Flores GuzmánBVinnakotaCGovindpaniK, et al.The GABAergic system as a therapeutic target for Alzheimer's disease. J Neurochem2018; 146: 649–669.
102.
ClaeysenSBockaertJGiannoniP. Serotonin: a new hope in Alzheimer's disease?ACS Chem Neurosci2015; 6: 940–943.
103.
FrancisPT. Glutamatergic systems in Alzheimer's disease. Int J Geriatr Psychiatry2003; 18: S15–S21.
104.
MartoranaAKochG. Is dopamine involved in Alzheimer's disease?Front Aging Neurosci2014; 6: 252.
105.
BevanRJHughesTRWilliamsPA, et al.Retinal ganglion cell degeneration correlates with hippocampal spine loss in experimental Alzheimer's disease. Acta Neuropathol Commun2020; 8: 216.
106.
BlumeTFilserSSgobioC, et al.β-secretase inhibition prevents structural spine plasticity deficits in App (NL-G-F) mice. Front Aging Neurosci2022; 14: 909586.
107.
HarkTJRaoNRCastillonC, et al.Pulse-chase proteomics of the app knockin mouse models of Alzheimer's disease reveals that synaptic dysfunction originates in presynaptic terminals. Cell Syst2021; 12: 141–158.e149.
